Get started
Author

Ben Tran

Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma
2023 · Yohann Loriot, Nobuaki Matsubara, et al. · New England Journal of Medicine · 371
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial
2023 · A.O. Siefker-Radtke, N. Matsubara, et al. · Annals of Oncology · 94
PDF
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer
2023 · J.W.F. Catto, B. Tran, et al. · Annals of Oncology · 87
PDF
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer
2020 · Srikala S. Sridhar, Normand Blais, et al. · JAMA Oncology · 38
PDF
A phase 3, single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
2022 · Edward M. Uchio, Donald L. Lamm, et al. · Journal of Clinical Oncology · 25
Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)
2023 · Andrew Weickhardt, Farshad Foroudi, et al. · European Urology Oncology · 22
Final Results: Bond-003 Cohort C- Phase 3, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for High-risk Bcg-unresponsive Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
2025 · Mark D. Tyson, Edward M. Uchio, et al. · The Journal of Urology · 17
Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study
2025 · Siamak Daneshmand, Renata Zaucha, et al. · European Urology · 12
A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy.
2020 · Gary D. Steinberg, Joan Palou-Redorta, et al. · Journal of Clinical Oncology · 12
Precision oncology in urothelial cancer
2020 · Elizabeth Liow, Ben Tran · ESMO Open · 11
PDF
Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 2 interim analysis results.
2023 · James W.F. Catto, Ben Tran, et al. · Journal of Clinical Oncology · 10
Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia
2023 · Howard Gurney, Timothy D. Clay, et al. · Asia-Pacific Journal of Clinical Oncology · 8
PDF
Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993).
2018 · Srikala S. Sridhar, Normand Blais, et al. · Journal of Clinical Oncology · 7
PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study
2025 · Cristian Udovicich, Mathias Bressel, et al. · Journal of Nuclear Medicine · 6
PDF
Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma
2024 · Justine Panian, Caiwei Zhong, et al. · European Urology Focus · 5
Risk stratification and management of non‐muscle‐invasive bladder cancer: A physician survey in six Asia‐Pacific territories
2023 · Ja Hyeon Ku, Lui Shiong Lee, et al. · International Journal of Urology · 4
PDF
A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301).
2025 · Aaron Richard Hansen, Alison Yan Zhang, et al. · Journal of Clinical Oncology · 3
Prognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting
2019 · K. Nekolla, N. Brieu, et al. · Annals of Oncology · 2
Abstract CT075: Phase 1a/1b dose-escalation study of efbalropendekin alfa (XmAb24306) as single-agent and with atezolizumab in solid tumors
2025 · Ben Tran, Anna Spreafico, et al. · Cancer Research · 1
Primary retroperitoneal lymph node dissection in stage II testicular seminoma: a systematic review
2024 · Jianliang Liu, Mrunal Hiwase, et al. · British Journal of Urology · 1
A multicenter randomized phase II trial comparing nab-paclitaxel to paclitaxel in patients with advanced urothelial cancer progressing on or after a platinum containing regimen: NCIC Clinical Trials Group BL 12 (NCT02033993).
2015 · Srikala S. Sridhar, Normand Blais, et al. · Journal of Clinical Oncology · 1
Pembrolizumab (pembro) with chemoradiotherapy (CRT) as treatment for muscle-invasive bladder cancer (MIBC): Long-term follow up of secondary endpoints of efficacy including overall survival of the PCR-MIB phase II clinical trial (ANZUP 1502).
2025 · Andrew James Weickhardt, Farshad Foroudi, et al. · Journal of Clinical Oncology
PDF
Abstract 5850: AXA-042, a systemically administered TLR2/6 agonist, demonstrates innate immune engagement and Th1 polarization in patients with advanced solid tumors
2025 · Ben Tran, Sophia Frentzas, et al. · Cancer Research
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).
2025 · Blossom Mak, Ben Tran, et al. · Journal of Clinical Oncology
PDF
35 Efficacy of treatments post-lenvatinib in patients with advanced renal cell carcinoma (aRCC)
2024 · Justine Panian, Caiwei Zhong, et al. · The Oncologist
PDF
Works count: 34
Citation count: 737
H-index: 10
I10-index: 11
Year
Topic
Type